Loading...
Amyloid positron emission tomography (PET) leads to changes in clinical management in nearly two thirds of patients with mild cognitive impairment or dementia of uncertain cause, according to an industry-supported study in JAMA.
Over 11,000 Medicare beneficiaries who'd been diagnosed with mild cognitive impairment or dementia by a dementia specialist underwent amyloid PET imaging. Results were considered positive in 55% of the mild cognitive impairment cohort and 70% of the dementia cohort.
Overall, 60% of those with mild cognitive impairment and 64% of those with dementia had a change in their clinical management between their pre- and postimaging assessment. For example, among those with positive PET results, use of Alzheimer drugs increase…